A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

ClinicalTrials.gov ID: NCT04064060

Public ClinicalTrials.gov record NCT04064060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Study identification

NCT ID: NCT04064060
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Celgene; Industry
Enrollment: 665 participants

Conditions and interventions

Conditions

Interventions

Luspatercept Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 11, 2019
Primary completion: May 11, 2028
Completion: May 11, 2028
Last update posted: Nov 11, 2025

2019 – 2028

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Childrens Hospital Los Angeles RHU	Los Angeles	California	90027-6062	Recruiting
Local Institution - 971	Oakland	California	94609	Completed
Local Institution - 978	Stanford	California	94305	Completed
Local Institution - 975	Tampa	Florida	33612	Completed
Local Institution - 970	Chicago	Illinois	60611	Completed
Local Institution - 973	Boston	Massachusetts	02115	Completed
Local Institution - 961	Detroit	Michigan	48201	Completed
Local Institution - 969	New York	New York	10065	Completed
Local Institution - 967	Cleveland	Ohio	44195	Active, not recruiting
Local Institution - 972	Philadelphia	Pennsylvania	19104	Completed
Vanderbilt - Ingram Cancer Center	Nashville	Tennessee	37232-5505	Withdrawn
The University of Texas - MD Anderson Cancer Center	Houston	Texas	77030	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 131 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04064060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 11, 2025 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04064060 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →